NO20060518L - Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler - Google Patents

Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler

Info

Publication number
NO20060518L
NO20060518L NO20060518A NO20060518A NO20060518L NO 20060518 L NO20060518 L NO 20060518L NO 20060518 A NO20060518 A NO 20060518A NO 20060518 A NO20060518 A NO 20060518A NO 20060518 L NO20060518 L NO 20060518L
Authority
NO
Norway
Prior art keywords
ion channels
modulators
voltage controlled
controlled ion
pyrimidines useful
Prior art date
Application number
NO20060518A
Other languages
English (en)
Inventor
Jesus E Gonzales Iii
Dean Mitchell Wilson
Esther Martinborough
Nicole Zimmermann
Timothy Donald Neuberg
Andreas Peter Termin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20060518L publication Critical patent/NO20060518L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse vedrører forbindelser som er nyttige som inhibitorer av spennings-portstyrte ione-kanaler. Oppfinnelsen tilveiebringer også farmasøytisk akseptable sammensetninger omfattende forbindelsene ifølge oppfinnelsen og metoder for å anvende sammensetningene i behandlingen av forskjellige forstyrrelser.
NO20060518A 2003-07-02 2006-02-01 Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler NO20060518L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48436203P 2003-07-02 2003-07-02
US50020003P 2003-09-04 2003-09-04
PCT/US2004/021440 WO2005003099A2 (en) 2003-07-02 2004-07-02 Pyrimidines useful as modulators of voltage-gated ion channels

Publications (1)

Publication Number Publication Date
NO20060518L true NO20060518L (no) 2006-03-07

Family

ID=33567720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060518A NO20060518L (no) 2003-07-02 2006-02-01 Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler

Country Status (14)

Country Link
US (2) US7816529B2 (no)
EP (1) EP1638955A2 (no)
JP (1) JP2007521287A (no)
KR (1) KR20060032190A (no)
AR (1) AR045010A1 (no)
AU (1) AU2004253962A1 (no)
CA (1) CA2531061A1 (no)
IL (1) IL172937A0 (no)
MX (1) MXPA06000051A (no)
NO (1) NO20060518L (no)
PE (1) PE20051029A1 (no)
RU (1) RU2006102955A (no)
TW (1) TW200519094A (no)
WO (1) WO2005003099A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060032190A (ko) * 2003-07-02 2006-04-14 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 이온 채널의 조절제로서 유용한 피리미딘
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
JP2008534472A (ja) * 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
JP2008540438A (ja) * 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリジン
WO2006119451A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
WO2006130493A2 (en) * 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
WO2007125331A2 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
AU2007258313A1 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用
US20080221103A1 (en) * 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
CN102558001B (zh) 2007-05-22 2015-09-23 惠氏有限责任公司 制造酰肼的改良方法
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
DK2214487T3 (da) * 2007-10-11 2014-02-10 Glaxosmithkline Llc Nye sEH-inhibitorer og deres anvendelse
DE102007061756A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
US20100311776A1 (en) * 2008-01-30 2010-12-09 Smithkline Beecham Corporation Novel sEH Inhibitors and their Use
US20100324076A1 (en) * 2008-01-30 2010-12-23 Joseph Paul Marino Novel sEH Inhibitors and their Use
WO2009097475A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
US20090198057A1 (en) * 2008-02-05 2009-08-06 Pu-Ping Lu Certain Chemical Entities, Compositions, and Methods
PE20110843A1 (es) 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
AR075196A1 (es) * 2009-02-03 2011-03-16 Otsuka Pharma Co Ltd Un derivado de cianopirimidina para el tratamiento de una enfermedad ocular
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
PT2616465E (pt) * 2010-09-13 2016-03-09 Novartis Ag Triazino-oxadiazoles
WO2013004332A1 (en) * 2011-07-07 2013-01-10 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
US10112929B2 (en) 2015-03-09 2018-10-30 Bristol-Myers Squibb Company Lactams as inhibitors of rock
GB201721751D0 (en) * 2017-12-22 2018-02-07 Adorx Therapeutics Ltd Compounds
WO2022217118A1 (en) * 2021-04-09 2022-10-13 Quanta Therapeutics, Inc. Pyrimidine based ras modulators and uses thereof
WO2023122780A2 (en) * 2021-12-23 2023-06-29 The Katholieke Universiteit Leuven 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB901749A (en) 1957-12-06 1962-07-25 Ciba Ltd New 2-substituted pyrimidines
US3040047A (en) 1960-04-04 1962-06-19 Takeda Pharmaceutical 2-(pyrazol-1-yl)-pyrimidine derivatives
US3850928A (en) 1969-11-04 1974-11-26 American Home Prod Substituted 6-alkylamino-2-phenyl-5-pyrimidine carboxylic acids
US3759922A (en) 1971-06-25 1973-09-18 American Home Prod Preparation of pyrimido(5,4-c)(1,5) benz oxazepin-5(11h)-ones and intermediates
US3850931A (en) 1971-06-25 1974-11-26 American Home Prod 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters
US3860596A (en) 1972-08-31 1975-01-14 American Home Prod 2-aryl-4-substituted-amino-5-pyrimidyl derivatives
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
FR2263750A1 (en) 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
FR2281117A2 (fr) 1974-08-09 1976-03-05 Ugine Kuhlmann Nouvelles piperazino-pyrimidines utilisables comme medicaments
JPS6044303B2 (ja) 1975-02-25 1985-10-02 大日本製薬株式会社 ２−環状アミノ−４−アミノピリミジン誘導体の製造法
DE3752141T2 (de) * 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
AU2003229305A1 (en) * 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
KR20060032190A (ko) * 2003-07-02 2006-04-14 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 이온 채널의 조절제로서 유용한 피리미딘
WO2006119451A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels

Also Published As

Publication number Publication date
US7816529B2 (en) 2010-10-19
CA2531061A1 (en) 2005-01-13
EP1638955A2 (en) 2006-03-29
PE20051029A1 (es) 2005-12-07
IL172937A0 (en) 2006-06-11
JP2007521287A (ja) 2007-08-02
US20110003814A1 (en) 2011-01-06
AR045010A1 (es) 2005-10-12
WO2005003099A3 (en) 2005-05-12
MXPA06000051A (es) 2006-03-21
TW200519094A (en) 2005-06-16
AU2004253962A1 (en) 2005-01-13
WO2005003099A2 (en) 2005-01-13
US8324220B2 (en) 2012-12-04
US20050049247A1 (en) 2005-03-03
KR20060032190A (ko) 2006-04-14
RU2006102955A (ru) 2007-08-20

Similar Documents

Publication Publication Date Title
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20061080L (no) Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
MX2010003009A (es) Piridil sulfonamidas como moduladores de canales ionicos.
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20082746L (no) Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler
WO2006050476A3 (en) Pyrimidine derivatives as ion channel modulators and methods of use
AU2008321142A8 (en) Heterocyclic derivatives as modulators of ion channels
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
WO2006130493A3 (en) Heterocycles useful as modulators of ion channels

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application